A Abella1, S García-Vicente1, N Viguerie2, A Ros-Baró1, M Camps1, M Palacín1, A Zorzano1, L Marti3. 1. Barcelona Science Parc and Department of Biochemistry and Molecular Biology, Faculty of Biology, Universitat de Barcelona, Josep Samitier, 1-5, 08028, Barcelona, Spain. 2. Research Unit on Obesity, French Institute of Health and Medical Research Unit 586, Louis Bugnard Institut, Rangueil Hospital, Université Paul Sabatier, Toulouse, France. 3. Barcelona Science Parc and Department of Biochemistry and Molecular Biology, Faculty of Biology, Universitat de Barcelona, Josep Samitier, 1-5, 08028, Barcelona, Spain. lmarti@bio.ub.es.
Abstract
AIMS/HYPOTHESIS: Vascular adhesion protein-1 (VAP-1), which is identical to semicarbazide-sensitive amine oxidase (SSAO), is a dual-function membrane protein with adhesion properties and amine oxidase activity. A soluble form of VAP-1 is found in serum, where concentrations are enhanced in diabetes and obesity. In vitro, soluble VAP-1 enhances lymphocyte adhesion to endothelial cells, thus possibly participating in the enhanced lymphocyte adhesion capacity that is implicated in the cardiovascular complications associated with diabetes or obesity. In both, the tissue origin of the soluble VAP-1/SSAO is unknown. We examined whether adipose tissue, which has abundant expression of VAP-1/SSAO, is a source of soluble VAP-1. METHODS: We detected VAP-1/SSAO in plasma of diabetic animals, with or without VAP-1 immunoprecipitation, and in culture medium from 3T3-L1 adipocytes and human adipose tissue explants. VAP-1 protein glycosylation was measured. RESULTS: Diabetic and obese animals have increased plasma SSAO activity associated with VAP-1 protein. We also found that 3T3-L1 adipocytes and human adipose tissue explants release a soluble form of VAP-1/SSAO, which derives from the membrane. The release of soluble VAP-1 was enhanced by exposure of murine and human adipocytes to TNF-alpha and blocked by batimastat, a metalloprotease inhibitor. Partial ablation of adipose tissue reduced plasma SSAO activity in normal and diabetic rats. CONCLUSIONS/ INTERPRETATION: Adipose cells are a source of soluble VAP-1/SSAO released by shedding of the membrane form. The release of SSAO is regulated by TNF-alpha and insulin. By releasing VAP-1/SSAO, adipose cells could contribute to the atherogenesis and vascular dysfunction associated with diabetes and obesity.
AIMS/HYPOTHESIS: Vascular adhesion protein-1 (VAP-1), which is identical to semicarbazide-sensitive amine oxidase (SSAO), is a dual-function membrane protein with adhesion properties and amine oxidase activity. A soluble form of VAP-1 is found in serum, where concentrations are enhanced in diabetes and obesity. In vitro, soluble VAP-1 enhances lymphocyte adhesion to endothelial cells, thus possibly participating in the enhanced lymphocyte adhesion capacity that is implicated in the cardiovascular complications associated with diabetes or obesity. In both, the tissue origin of the soluble VAP-1/SSAO is unknown. We examined whether adipose tissue, which has abundant expression of VAP-1/SSAO, is a source of soluble VAP-1. METHODS: We detected VAP-1/SSAO in plasma of diabetic animals, with or without VAP-1 immunoprecipitation, and in culture medium from 3T3-L1 adipocytes and human adipose tissue explants. VAP-1 protein glycosylation was measured. RESULTS:Diabetic and obese animals have increased plasma SSAO activity associated with VAP-1 protein. We also found that 3T3-L1 adipocytes and human adipose tissue explants release a soluble form of VAP-1/SSAO, which derives from the membrane. The release of soluble VAP-1 was enhanced by exposure of murine and human adipocytes to TNF-alpha and blocked by batimastat, a metalloprotease inhibitor. Partial ablation of adipose tissue reduced plasma SSAO activity in normal and diabeticrats. CONCLUSIONS/ INTERPRETATION: Adipose cells are a source of soluble VAP-1/SSAO released by shedding of the membrane form. The release of SSAO is regulated by TNF-alpha and insulin. By releasing VAP-1/SSAO, adipose cells could contribute to the atherogenesis and vascular dysfunction associated with diabetes and obesity.
Authors: R Marfella; K Esposito; R Giunta; G Coppola; L De Angelis; B Farzati; G Paolisso; D Giugliano Journal: Circulation Date: 2000-05-16 Impact factor: 29.690
Authors: S García-Vicente; A Abella; N Viguerie; A Ros-Baró; M Camps; X Testar; M Palacín; A Zorzano; L Marti Journal: J Physiol Biochem Date: 2005-06 Impact factor: 4.158
Authors: Tomi T Airenne; Yvonne Nymalm; Heidi Kidron; David J Smith; Marjo Pihlavisto; Marko Salmi; Sirpa Jalkanen; Mark S Johnson; Tiina A Salminen Journal: Protein Sci Date: 2005-08 Impact factor: 6.725
Authors: Nadia Ayala-Lopez; William F Jackson; Robert Burnett; James N Wilson; Janice M Thompson; Stephanie W Watts Journal: Am J Physiol Heart Circ Physiol Date: 2015-10-02 Impact factor: 4.733
Authors: F Boomsma; U Pedersen-Bjergaard; B Agerholm-Larsen; H Hut; S S Dhamrait; B Thorsteinsson; A H van den Meiracker Journal: Diabetologia Date: 2005-04-14 Impact factor: 10.122
Authors: Serena Becchi; Alberto Buson; Jonathan Foot; Wolfgang Jarolimek; Bernard W Balleine Journal: Br J Pharmacol Date: 2017-06-10 Impact factor: 8.739